Pathogenesis of myeloma bone disease

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Myeloma bone disease is characterized by osteolytic bone destruction that is not followed by reactive new bone formation. This results in a purely lytic process, which differs from other cancers that metastasize to bone where bone destruction is followed by new bone formation. The bone destructive process in myeloma is mediated by the osteoclast (OCL), the normal bone resorbing cell. Factors that increase OCL formation and activity are produced by both myeloma cells themselves, as well as by marrow stromal cells when myeloma cells bind to marrow stromal cells. The bone destructive process releases factors that further increase the growth and survival of myeloma cells. Thus, there is a symbiotic relationship between the bone destructive process and increased growth of myeloma cells. Several studies have shown that blocking bone destruction can result in decreased tumor burden in animal models of myeloma. This overview will focus on the factors recently identified that appear to play an important role in the bone destructive process in myeloma.

Original languageEnglish (US)
Pages (from-to)290-292
Number of pages3
JournalBlood Cells, Molecules and Diseases
Volume32
Issue number2
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Bone Diseases
Bone and Bones
Osteoclasts
Stromal Cells
Osteogenesis
Bone Marrow
Growth
Tumor Burden
Cell Survival
Animal Models

Keywords

  • Bone destruction
  • Myeloma
  • Osteoclast

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology

Cite this

Pathogenesis of myeloma bone disease. / Roodman, G. David.

In: Blood Cells, Molecules and Diseases, Vol. 32, No. 2, 03.2004, p. 290-292.

Research output: Contribution to journalArticle

@article{de6a75b3bfe04f3bb9f264afad5a0c04,
title = "Pathogenesis of myeloma bone disease",
abstract = "Myeloma bone disease is characterized by osteolytic bone destruction that is not followed by reactive new bone formation. This results in a purely lytic process, which differs from other cancers that metastasize to bone where bone destruction is followed by new bone formation. The bone destructive process in myeloma is mediated by the osteoclast (OCL), the normal bone resorbing cell. Factors that increase OCL formation and activity are produced by both myeloma cells themselves, as well as by marrow stromal cells when myeloma cells bind to marrow stromal cells. The bone destructive process releases factors that further increase the growth and survival of myeloma cells. Thus, there is a symbiotic relationship between the bone destructive process and increased growth of myeloma cells. Several studies have shown that blocking bone destruction can result in decreased tumor burden in animal models of myeloma. This overview will focus on the factors recently identified that appear to play an important role in the bone destructive process in myeloma.",
keywords = "Bone destruction, Myeloma, Osteoclast",
author = "Roodman, {G. David}",
year = "2004",
month = "3",
doi = "10.1016/j.bcmd.2004.01.001",
language = "English (US)",
volume = "32",
pages = "290--292",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Pathogenesis of myeloma bone disease

AU - Roodman, G. David

PY - 2004/3

Y1 - 2004/3

N2 - Myeloma bone disease is characterized by osteolytic bone destruction that is not followed by reactive new bone formation. This results in a purely lytic process, which differs from other cancers that metastasize to bone where bone destruction is followed by new bone formation. The bone destructive process in myeloma is mediated by the osteoclast (OCL), the normal bone resorbing cell. Factors that increase OCL formation and activity are produced by both myeloma cells themselves, as well as by marrow stromal cells when myeloma cells bind to marrow stromal cells. The bone destructive process releases factors that further increase the growth and survival of myeloma cells. Thus, there is a symbiotic relationship between the bone destructive process and increased growth of myeloma cells. Several studies have shown that blocking bone destruction can result in decreased tumor burden in animal models of myeloma. This overview will focus on the factors recently identified that appear to play an important role in the bone destructive process in myeloma.

AB - Myeloma bone disease is characterized by osteolytic bone destruction that is not followed by reactive new bone formation. This results in a purely lytic process, which differs from other cancers that metastasize to bone where bone destruction is followed by new bone formation. The bone destructive process in myeloma is mediated by the osteoclast (OCL), the normal bone resorbing cell. Factors that increase OCL formation and activity are produced by both myeloma cells themselves, as well as by marrow stromal cells when myeloma cells bind to marrow stromal cells. The bone destructive process releases factors that further increase the growth and survival of myeloma cells. Thus, there is a symbiotic relationship between the bone destructive process and increased growth of myeloma cells. Several studies have shown that blocking bone destruction can result in decreased tumor burden in animal models of myeloma. This overview will focus on the factors recently identified that appear to play an important role in the bone destructive process in myeloma.

KW - Bone destruction

KW - Myeloma

KW - Osteoclast

UR - http://www.scopus.com/inward/record.url?scp=1542330894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542330894&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2004.01.001

DO - 10.1016/j.bcmd.2004.01.001

M3 - Article

VL - 32

SP - 290

EP - 292

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 2

ER -